Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

KemPharm, Inc. - Common Stock (NQ: KMPH )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about KemPharm, Inc. - Common Stock

< Previous 1 2 Next >
CORRECTION – KemPharm Announces Corporate Name Change to Zevra Therapeutics
From KemPharm
Via GlobeNewswire
KemPharm Announces Corporate Name Change to Zevra Therapeutics
From KemPharm
Via GlobeNewswire
This Rare Disease Focused Stock Pipeline Is Underappreciated, Analyst Initiating Coverage Says
Via Benzinga
KemPharm's Earnings: A Preview
KemPharm (NASDAQ:KMPH) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that KemPharm will... 
Via Benzinga
KemPharm's Lead Prodrug Shows Favorable Safety Profile For Rare Sleeping Disorder
Via Benzinga
Recap: KemPharm Q2 Earnings
  KemPharm (NASDAQ:KMPH) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
KemPharm Acquires Battered Orphazyme's Arimoclomol Program For $13M
Via Benzinga
KemPharm's SDX Higher Dose Shows Potential Against Sleep Disorders
KemPharm Inc (NASDAQ: KMPH)  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
Upgrades 
Via Benzinga
US Stocks Turn Lower; Nasdaq Drops Over 100 Points
U.S. stocks turned lower midway through trading, with the Nasdaq Composite dropping more than 100 points on Thursday. 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2022
Upgrades 
Via Benzinga
Apple To $220? Here Are 5 Other Price Target Changes For Wednesday
Wedbush raised the price target on Apple Inc. (NASDAQ: AAPL) from $200 to $220. However, Wedbush analyst Daniel Ives maintained the stock with an Outperform. Apple shares fell 0.2% to $172.69 in... 
Via Benzinga
Recap: KemPharm Q1 Earnings
KemPharm (NASDAQ:KMPH) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings KemPharm reported in-line EPS of... 
Via Benzinga
Earnings Preview For KemPharm
KemPharm (NASDAQ:KMPH) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that KemPharm will... 
Via Benzinga
The Technology Helping Existing FDA-Approved Drugs Target More Effectively
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Benzinga Announces This Week's All Access Guests
Benzinga is thrilled to announce the guest lineup for our next All Access show, sponsored by TiiCKER, set to air Friday, April 29 at 9:15 am ET. The Lineup 9:15 am: Opening Remarks 9:40 am: Save Foods... 
Via Benzinga
26 Stocks Moving in Monday's Pre-Market Session
Gainers ERYTECH Pharma S.A. (NASDAQ: ERYP) shares rose 88.4% to $2.30 in pre-market trading. Erytech Pharma recently announced publication of results from Eryapasse Phase 2 trial... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 92 companies hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week... 
Via Benzinga
Earnings Scheduled For March 30, 2022
Companies Reporting Before The Bell • Orgenesis (NASDAQ:ORGS) is likely to report earnings for its fourth quarter. • RumbleON (NASDAQ:RMBL) is estimated to report earnings for its Fiscal Year 2021. 
Via Benzinga
KemPharm To Develop KP1077 As Lead SDX Candidate For Chronic Sleep Disorder
KemPharm Inc (NASDAQ: KMPH) has selected KP1077 for idiopathic hypersomnia (IH) as its lead serdexmethylphenidate (SDX) candidate in the pipeline. Idiopathic hypersomnia is... 
Via Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets. 
Via Benzinga
38 Stocks Moving In Monday's Mid-Day Session
Gainers Society Pass Incorporated (NASDAQ: SOPA) shares jumped 120.9% to $7.31 after the company reported addition to the Russell 2000 Index. Can-Fite BioPharma Ltd. (NYSE: CANF... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 115 companies reached new 52-week lows. Noteworthy Points From Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022
Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago... 
Via Benzinga
Why KemPharm Stock Sank Today
Investors reacted negatively to the company's warrant exchange. 
Via The Motley Fool
65 Biggest Movers From Yesterday
Gainers Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index. Bluerock... 
Via Benzinga
78 Biggest Movers From Friday
Gainers PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares jumped 43.4% to close at $3.27. PharmaCyte Biotech recently reported closing of $15-million public offering. Flora Growth... 
Via Benzinga
53 Stocks Moving In Friday's Mid-Day Session
Gainers BIOLASE, Inc. (NASDAQ: BIOL) shares climbed 30.9% to $0.8270 after the company reported better-than-expected Q2 sales. The company said it continues to experience demand... 
Via Benzinga
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures COVID-19
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.